Pharmacogenetics of coumarin anticoagulant therapy
Publication date
2015-05-03
Authors
van Schie, Rianne M. F.
Verhoef, Talitha I.
De Boer, Anthonius
van der Meer, Felix J. M.
Redekop, William K.
Schalekamp, Tom
Maitland-Van der Zee, Anke-Hilse
Editors
Grech, Godfrey
Advisors
Supervisors
Document Type
Part of book
Metadata
Show full item recordCollections
License
taverne
Abstract
Coumarins are effective drugs for treatment and prevention of thromboembolic events. However, their use requires a balancing act between the chance of underdosing which increases the risk of thromboembolic events and the chance of overdosing which increases the risk of haemorrhages. It has been shown that polymorphisms in VKORC1 and CYP2C9 explain 35-50% of the dose variability, although patient characteristics and environmental factors also play a role. In this book chapter we discuss the pharmacogenetics of coumarin derivatives, clinical trials investigating the effectiveness of pre-treatment genotyping and the cost-effectiveness of pharmacogenetic-guided dosing.
Keywords
Adverse drug reaction, Pharmacogenetics, Predictive genotyping, Translation, abacavir, coumarin, phenprocoumon, warfarin, anticoagulant therapy, bleeding, clinical practice, clinical trial (topic), cost effectiveness analysis, drug stability, environmental factor, genetic polymorphism, genetic variability, genotype, human, pharmacogenetics, predictive value, quality adjusted life year, thrombocytopenia, venous thromboembolism, Taverne, SDG 3 - Good Health and Well-being
Citation
van Schie, R M F, Verhoef, T I, de Boer, A, van der Meer, F J M, Redekop, W K, Schalekamp, T & Maitland-Van der Zee, A-H 2015, Pharmacogenetics of coumarin anticoagulant therapy. in G Grech (ed.), Preventive and Predictive Genetics : Towards Personalised Medicine. Advances in Predictive, Preventive and Personalised Medicine , vol. 9, Kluwer Academic, pp. 307-328. https://doi.org/10.1007/978-3-319-15344-5_11